Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials

Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials

ObjectiveAlthough dual anti-HER2 therapy, namely, pertuzumab plus trastuzumab, has shown promising results in patients with HER2-positive breast cancer (BC), it is still unclear whether dual therapy will increase adverse effects (AEs) while ensuring the efficacy compared with trastuzumab monotherapy...

Full description

Bibliographic Details
Main Authors: Xiaoyun Liu, Yingying Fang, Yinjuan Li, Yan Li, Lu Qi, Xinghe Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
breast cancer
HER2-positive
pertuzumab
trastuzumab
meta-analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.894861/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.894861/full

Similar Items